Clinical Data New data build case for Roche’s oral BTK drug for MS PharmaphorumRoche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.Clinical DataNeuroscienceRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns. Clinical DataNeuroscienceRead full story Post navigation Previous: Pivotal trial of Moderna’s H5N1 bird flu jab gets underwayNext: MSD-backed Ray locks in $125m to back eye drug pipeline Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
